Molecular targeted intervention for pancreatic cancer

Cancers

Volumn 7, Issue 3, 2015, Pages 1499-1542

  Mohammed, Altaf ^a   Janakiram, Naveena B ^a   Pant, Shubham ^a   Rao, Chinthalapally V ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Chemoprevention; Chemotherapy; Combination treatment; Drug development; Pancreatic cancer

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CELECOXIB; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2; CYTOTOXIC AGENT; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IRINOTECAN; K RAS PROTEIN; LICOFELONE; MAMMALIAN TARGET OF RAPAMYCIN; MUCIN 1; NIMESULIDE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SULINDAC; TEMSIROLIMUS; TIPIFARNIB; UFT; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CHEMOPROPHYLAXIS; CHEMORADIOTHERAPY; DIET SUPPLEMENTATION; DISEASE MODEL; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TARGETING; GENE TARGETING; GENETIC ENGINEERING; HUMAN; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MOUSE MODEL; NONHUMAN; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREAS METASTASIS; PANCREAS TUMOR; PATHOLOGY; PROTEIN TARGETING; REVIEW; TUMOR MICROENVIRONMENT;

EID: 84940989434     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers7030850     Document Type: Review

References (191)

1. American Cancer Society. Cancer Facts and Figures 2015; American Cancer Society (ACS): Atlanta, GA, USA, 2015.
2. Burris, H.A., 3rd; Moore, M.J.; Andersen, J.; Green, M.R.; Rothenberg, M.L.; Modiano, M.R.; Cripps, M.C.; Portenoy, R.K.; Storniolo, A.M.; Tarassoff, P.; et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J. Clin. Oncol. 1997, 15, 2403-2413.
3. Heinemann, V. Gemcitabine: Progress in the treatment of pancreatic cancer. Oncology 2001, 60, 8-18. [CrossRef] [PubMed]
4. Mamon, H.J.; Niedzwiecki, D.; Hollis, D.; Tan, B.R.; Mayer, R.J.; Tepper, J.E.; Goldberg, R.M.; Blackstock, A.W.; Fuchs, C.S. A phase 2 trial of gemcitabine, 5-florouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma: Cancer and Leukemia Group B (CALGB) 80003. Cancer 2011, 117, 2620-2628. [CrossRef] [PubMed]
5. Kim, M.P.; Gallick, G.E. Gemcitabine resistance in pancreatic cancer: Picking the key players. Clin. Cancer Res. 2008, 14, 1284-1285. [CrossRef] [PubMed]
6. Hidalgo, M. Pancreatic cancer. N. Engl. J. Med. 2010, 362, 1605-1617. [CrossRef] [PubMed]
7. Eckel, F.; Schneider, G.; Schmid, R.M. Pancreatic cancer: A review of recent advances. Exp. Opin. Investig. Drugs 2006, 15, 1395-1410. [CrossRef] [PubMed]
8. Mohammed, A.; Janakiram, N.B.; Lightfoot, S.; Gali, H.; Vibhudutta, A.; Rao, C.V. Early Detection and Prevention of Pancreatic Cancer: Use of Genetically Engineered Mouse Models and advanced Imaging Technologies. Curr. Med. Chem. 2012, 19, 3701-3713. [CrossRef] [PubMed]
9. Sayers, H.J.; Orloff, M.J. Development of an animal model of pancreatic cancer. Surg. Forum 1976, 27, 456-458. [PubMed]
10. Morosco, G.J.; Goeringer, G.C. Lifestyle factors and cancer of the pancreas: A hypothetical mechanism. Med. Hypotheses 1980, 6, 971-985. [CrossRef]
11. Berlin, N.I. Williams M. Pancreatic cancer: An epidemiologic approach and model. J. Am. Med. Assoc. 1981, 245, 171. [CrossRef]
12. Hruban, R.H.; Goggins, M.; Parsons, J.; Kern, S.E. Progression model for pancreatic cancer. Clin. Cancer Res. 2000, 6, 2969-2972. [PubMed]
13. Mazur, P.K.; Siveke, J.T. Genetically Engineered mouse models of pancreatic cancer: Unravelling tumor biology and progressing translational oncology. Gut 2012, 61, 1488-1500. [CrossRef] [PubMed]
14. Mihaljevic, A.L.; Michalski, C.W.; Friess, H.; Kleeff, J. Molecular mechanism of pancreatic cancer-Understanding proliferation, invasion, and metastasis. Langenbecks Arch. Surg. 2010, 395, 295-308. [CrossRef] [PubMed]
15. Hong, S.M.; Park, J.Y.; Hruban, R.H.; Goggins, M. Molecular Signatures of Pancreatic Cancer. Arch. Pathol. Lab. Med. 2011, 135, 716-727. [PubMed]
16. Feldmann, G.; Beaty, R.; Hruban, R.H.; Maitra, A. Molecular genetics of pancreatic intraepithelial neoplasia. J. Hepato-Biliary-Pancreat Surg. 2007, 14, 224-232. [CrossRef] [PubMed]
17. Hilgers, W.; Kern, S.E. Molecular Genetic Basis of Pancreatic Adenocarcinoma. Genes Chromosom. Cancer 1999, 26, 1-12. [CrossRef]
18. Feldmann, G.; Habbe, N.; Dhara, S.; Bisht, S.; Alvarez, H.; Fendrich, V.; Beaty, R.; Mullendore, M.; Karikari, C.; Bardeesy, N.; et al. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 2008, 57, 1420-1430. [CrossRef] [PubMed]
19. Ottenhof, N.A.; Milne, A.N.; Morsink, F.H.; Drillenburg, P.; Ten Kate, F.J.; Maitra, A.; Offerhaus, G.J. Pancreatic Intraepithelial Neoplasia and Pancreatic Tumorigenesis of Mice and Men. Arch. Pathol. Lab. Med. 2009, 133, 375-381. [PubMed]
20. Jones, S.; Zhang, X.; Parsons, D.W.; Lin, J.C.; Leary, R.J.; Angenendt, P.; Mankoo, P.; Carter, H.; Kamiyama, H.; Jimeno, A.; et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321, 1801-1806. [CrossRef] [PubMed]
21. Haas, M.; Laubender, R.P.; Stieber, P.; Holdenrieder, S.; Bruns, C.J.; Wilkowski, R.; Mansmann, U.; Heinemann, V.; Boeck, S. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. Tumour Biol. 2010, 31, 351-357. [CrossRef] [PubMed]
22. Ho, J.J.; Siddiki, B.; Kim, Y.S. Association of sialyl-Lewis(a) and sialyl-Lewis(x) with MUC-1 apomucin ina pancreatic cancer cell line. Cancer Res. 1995, 55, 3659-3663. [PubMed]
23. Steinberg, W. The clinical utility of the CA 19-9 tumor-associated antigen. Am. J. Gastroenterol. 1990, 85, 350-355. [PubMed]
24. Andren-Sandberg, A. CA 50 and CA 19-9 in serum as tumor markers for pancreatic cancer: A review of the literature. Acta Chir. Scand. 1989, 549, 75-81.
25. Kokhanenko, N.; Ignashov, A.M.; Varga, E.V.; Polkanova, M.S.; Aleshina, L.A.; Kimbarovskaia, A.A.; Osipenko, S.K.; Lebedev, E.G. Role of the tumor markers CA 19-9 and carcinoembryonic antigen (CEA) in diagnosis, treatment and prognosis of pancreatic cancer. Vopr. Onkol. 2001, 47, 294-297. [PubMed]
26. Baeckstrom, D.; Hansson, G.C.; Nilsson, O.; Johansson, C.; Gendler, S.J.; Lindholm, L. Purification and characterization of a membrane-bound and a secreted mucin-type glycoprotein carrying the carcinoma-associated sialyl-Lea epitope on distinct core proteins. J. Biol. Chem. 1991, 266, 21537-21547. [PubMed]
27. Kelly, K.A.; Bardeesy, N.; Anbazhagan, R.; Gurumurthy, S.; Berger, J.; Alencar, H.; Depinho, R.A.; Mahmood, U.; Weissleder, R. Targeted Nanoparticles for Imaging Incipient Pancreatic Ductal Adenocarcinoma. PLoS Med. 2008, 5, e85. [CrossRef] [PubMed]
28. Haug, U.; Wente, M.N.; Seiler, C.M.; Jesenofsky, R.; Brenner, H. Stool testing for the early detection of pancreatic cancer: Rationale and current evidence. Exp. Rev. Mol. Diagn. 2008, 8, 753-759. [CrossRef] [PubMed]
29. Hingorani, S.R.; Wang, L.; Multani, A.S.; Combs, C.; Deramaudt, T.B.; Hruban, R.H.; Rustgi, A.K.; Chang, S.; Tuveson, D.A. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005, 7, 469-483. [CrossRef] [PubMed]
30. Izeradjene, K.; Combs, C.; Best, M.; Gopinathan, A.; Wagner, A.; Grady, W.M.; Deng, C.X.; Hruban, R.H.; Adsay, N.V.; Tuveson, D.A.; et al. KrasG12D and Smad4/Dpc4 Haploinsufficiency Cooperate to Induce Mucinous Cystic Neoplasms and Invasive Adenocarcinoma of the Pancreas. Cancer Cell 2007, 11, 229-243. [CrossRef] [PubMed]
31. Shi, G.; Zhu, L.; Sun, Y.; Bettencourt, R.; Damsz, B.; Hruban, R.H.; Konieczny, S.F. Loss of the Acinar-Restricted Transcription Factor Mist1 Accelerates Kras-Induced Pancreatic Intraepithelial Neoplasia. Gastroenterology 2009, 136, 1368-1378. [CrossRef] [PubMed]
32. Tuveson, D.A.; Zhu, L.; Gopinathan, A.; Willis, N.A.; Kachatrian, L.; Grochow, R.; Pin, C.L.; Mitin, N.Y.; Taparowsky, E.J.; Gimotty, P.A.; et al. Mist1-KrasG12D Knock-In Mice Develop Mixed Differentiation metastatic Exocrine Pancreatic Carcinoma and Hepatocellular Carcinoma. Cancer Res. 2006, 66, 242-247. [CrossRef] [PubMed]
33. Grippo, P.J.; Nowlin, P.S.; Demeure, M.J.; Longnecker, D.S.; Sandgren, E.P. Preinvasive pancreatic neoplasia of ductal phenotype induced by acinar cell targeting of mutant Kras in transgenic mice. Cancer Res. 2003, 63, 2016-2019. [PubMed]
34. Hingorani, S.R.; Petricoin, E.; Maitra, A.; Rajapakse, V.; King, C.; Jacobetz, M.A.; Ross, S.; Conrads, T.P.; Veenstra, T.D.; Hitt, B.A.; et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003, 4, 437-450. [CrossRef]
35. Yachida, S.; Jones, S.; Bozic, I.; Antal, T.; Leary, R.; Fu, B.; Kamiyama, M.; Hruban, R.H.; Eshleman, J.R.; Nowak, M.A.; et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010, 467, 1114-1117. [CrossRef] [PubMed]
36. Moore, M.; Goldstein, D.; Hamm, J.; Figer, A.; Hecht, J.R.; Gallinger, S.; Au, H.J.; Murawa, P.; Walde, D.; Wolff, R.A.; et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007, 25, 1960-1966. [CrossRef] [PubMed]
37. Conroy, T.; Desseigne, F.; Ychou, M.; Bouché, O.; Guimbaud, R.; Bécouarn, Y.; Adenis, A.; Raoul, J.L.; Gourgou-Bourgade, S.; de la Fouchardière, C.; et al. FOLFIRINOX vs. gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011, 364, 1817-1825. [CrossRef] [PubMed]
38. Von Hoff, D.D.; Ervin, T.J.; Arena, F.P.; Chiorean, G.; Infante, J.R.; Moore, M.J.; Seay, T.E.; Tjulandin, S.; Ma, W.W.; Saleh, M.N.; et al. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine vs. gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). J. Clin. Oncol. 2012, 30, LBA148.
39. Ren, Y.X.; Xu, G.M.; Li, Z.S.; Song, Y.J. Detection of point mutation in Kras oncogene at codon 12 in pancreatic diseases. World J. Gastroenterol. 2004, 10, 881-884. [PubMed]
40. Cohen, S.J.; Ho, L.; Ranganathan, S.; Abbruzzese, J.L.; Alpaugh, R.K.; Beard, M.; Lewis, N.L.; McLaughlin, S.; Rogatko, A.; Perez-Ruixo, J.J.; et al. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J. Clin. Oncol. 2003, 21, 1301-1306. [CrossRef] [PubMed]
41. Macdonald, J.S.; McCoy, S.; Whitehead, R.P.; Iqbal, S.; Wade, J.L., 3rd; Giguere, J.K.; Abbruzzese, J.L. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A southwest oncology group (SWOG 9924) study. Investig. New Drugs 2005, 23, 485-487. [CrossRef] [PubMed]
42. Van Cutsem, E.; van de Velde, H.; Karasek, P.; Oettle, H.; Vervenne, W.L.; Szawlowski, A.; Schoffski, P.; Post, S.; Verslype, C.; Neumann, H.; et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 2004, 22, 1430-1438. [CrossRef] [PubMed]
43. Martin, N.E.; Brunner, T.B.; Kiel, K.D.; DeLaney, T.F.; Regine, W.F.; Mohiuddin, M.; Rosato, E.F.; Haller, D.G.; Stevenson, J.P.; Smith, D.; et al. A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer. Clin. Cancer Res. 2004, 10, 5447-5454. [CrossRef] [PubMed]
44. Gjertsen, M.K.; Buanes, T.; Rosseland, A.R.; Bakka, A.; Gladhaug, I.; Søreide, O.; Eriksen, J.A.; Møller, M.; Baksaas, I.; Lothe, R.A.; et al. Intradermal ras peptide vaccination with granulocyte macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int. J. Cancer 2001, 92, 441-450. [CrossRef] [PubMed]
45. Muscarella, P.; Wilfong, L.S.; Ross, S.B.; Richards, D.A.; Raynov, J.; Fisher, W.E.; Flynn, P.J.; Whiting, S.H.; Rosemurgy, A.; Harrell, F.E.; et al. A randomized, placebo controlled, double blind, multicenter phase 2 adjuvant trial of the efficacy, immunogeneicity, and safety of GI-4000 plus Gem vs. Gem alone in patients with resected pancreas cancer with activating Ras mutations/survival and immunology analysis of the R1 Subgroup. J. Clin. Oncol. 2012, 30, e14501.
46. Navas, C.; Hernández-Porras, I.; Schuhmacher, A.J.; Sibilia, M.; Guerra, C.; Barbacid, M. Egf receptor signaling is essential for Kras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell 2012, 22, 318-330. [CrossRef] [PubMed]
47. Ardito, C.M.; Grüner, B.M.; Takeuchi, K.K.; Lubeseder-Martellato, C.; Teichmann, N.; Mazur, P.K.; Delgiorno, K.E.; Carpenter, E.S.; Halbrook, C.J.; Hall, J.C.; et al. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 2012, 22, 304-317. [CrossRef] [PubMed]
48. Xiong, H.Q.; Rosenberg, A.; LoBuglio, A.; Schmidt, W.; Wolff, R.A.; Deutsch, J.; Needle, M.; Abbruzzese, J.L. Cetuximab, a monoclonal antibody targeting the epidermal factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II trial. J. Clin. Oncol. 2004, 22, 2610-2616. [CrossRef] [PubMed]
49. Cascinu, S.; Berardi, R.; Labianca, R.; Siena, S.; Falcone, A.; Aitini, E.; Barni, S.; Di Costanzo, F.; Dapretto, E.; Tonini, G.; et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: A randomised, multicentre, phase II trial. Lancet Oncol. 2008, 9, 39-44. [CrossRef]
50. Philip, P.A.; Benedetti, J.; Corless, C.L.; Wong, R.; O'Reilly, E.M.; Flynn, P.J.; Rowland, K.M.; Atkins, J.N.; Mirtsching, B.C.; Rivkin, S.E.; et al. Phase III study comparing gemcitabine plus cetuximab vs. gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest oncology group-Directed intergroup trial S0205. J. Clin. Oncol. 2010, 28, 3605-3610. [CrossRef] [PubMed]
51. G12D transgenic mouse model. Cancer Prev. Res. 2010, 3, 1417-1426. [CrossRef] [PubMed]
52. Molina, M.A.; Sitja-Arnau, M.; Lemoine, M.G.; Frazier, M.L.; Sinicrope, F.A. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999, 59, 4356-4362. [PubMed]
53. Tucker, O.N.; Dannenberg, A.J.; Yang, E.K.; Zhang, F.; Teng, L.; Daly, J.M.; Soslow, R.A.; Masferrer, J.L.; Woerner, B.M.; Koki, A.T.; et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999, 59, 987-990. [PubMed]
54. Koshiba, T.; Hosotani, R.; Miyamoto, Y.; Wada, M.; Lee, J.U.; Fujimoto, K.; Tsuji, S.; Nakajima, S.; Doi, R.; Imamura, M. Immunohisto-chemical analysis of cyclooxygenase-2 expression in pancreatic tumors. Int. J. Pancreatol. 1999, 26, 69-76. [CrossRef] [PubMed]
55. Okami, J.; Yamamoto, H.; Fujiwara, Y.; Tsujie, M.; Kondo, M.; Noura, S.; Oshima, S.; Nagano, H.; Dono, K.; Umeshita, K.; et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin. Cancer Res. 1999, 5, 2018-2024. [PubMed]
56. Yip-Schneider, M.T.; Barnard, D.S.; Billings, S.D.; Cheng, L.; Heilman, D.K.; Lin, A.; Marshall, S.J.; Crowell, P.L.; Marshall, M.S.; Sweeney, C.J. Cyclooxygenase-2 expression in human pancreatic adenocarci-nomas. Carcinogenesis 2000, 21, 139-146. [CrossRef] [PubMed]
57. Kokawa, A.; Kondo, H.; Gotoda, T.; Ono, H.; Saito, D.; Nakadaira, S.; Kosuge, T.; Yoshida, S. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 2001, 91, 333-338. [CrossRef]
58. Maitra, A.; Ashfaq, R.; Gunn, C.R.; Rahman, A.; Yeo, C.J.; Sohn, T.A.; Cameron, J.L.; Hruban, R.H.; Wilentz, R.E. Cyclooxygenase 2 Expression in Pancreatic Adenocarcinoma and Pancreatic Intraepithelial Neoplasia: An Immunohistochemical Analysis With Automated Cellular Imaging. Am. J. Clin. Pathol. 2002, 118, 194-201. [CrossRef] [PubMed]
59. El-Rayes, B.F.; Zalupski, M.M.; Shields, A.F.; Ferris, A.M.; Vaishampayan, U.; Heilbrun, L.K.; Venkatramanamoorthy, R.; Adsay, V.; Philip, P.A. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Investig. New Drugs 2005, 23, 583-590. [CrossRef] [PubMed]
60. Ferrari, V.; Valcamonico, F.; Amoroso, V.; Simoncini, E.; Vassalli, L.; Marpicati, P.; Rangoni, G.; Grisanti, S.; Tiberio, G.A.; Nodari, F.; et al. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: A phase II trial. Cancer Chemother. Pharmacol. 2006, 57, 185-190. [CrossRef] [PubMed]
61. Morak, M.J.; Richel, D.J.; van Eijck, C.H.; Nuyttens, J.J.; van der Gaast, A.; Vervenne, W.L.; Padmos, E.E.; Schaake, E.E.; Busch, O.R.; van Tienhoven, G. Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer. Radiother. Oncol. 2011, 98, 261-264. [CrossRef] [PubMed]
62. Mukherjee, P.; Basu, G.D.; Tinder, T.L.; Subramani, D.B.; Bradley, J.M.; Arefayene, M.; Skaar, T.; de Petris, G. Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J. Immunol. 2009, 182, 216-224. [CrossRef] [PubMed]
63. Yip-Schneider, M.T.; Wu, H.; Hruban, R.H.; Lowy, A.M.; Crooks, P.A.; Schmidt, C.M. Efficacy of dimethylaminoparthenolide and sulindac in combination with gemcitabine in a genetically engineered mouse model of pancreatic cancer. Pancreas 2013, 42, 160-167. [CrossRef] [PubMed]
64. G12D mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Res. 2007, 67, 7068-7071. [CrossRef] [PubMed]
65. G12D/+ mice. Neoplasia 2012, 14, 778-787. [CrossRef] [PubMed]
66. Steinhilber, D.; Fischer, A.S.; Metzner, J.; Steinbrink, S.D.; Roos, J.; Ruthardt, M.; Maier, T.J. 5-Lipoxygenase: Underappreciated role of a pro-inflammatory enzyme in tumorigenesis. Front. Pharmacol. 2010, 1, 143. [CrossRef] [PubMed]
67. Ding, X.Z.; Hennig, R.; Adrian, T.E. Lipoxygenase and cyclooxygenase metabolism: New insights in treatment and chemoprevention of pancreatic cancer. Mol. Cancer 2003, 2, 10. [CrossRef] [PubMed]
68. Funk, C.D. Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science 2001, 294, 1871-1875. [CrossRef] [PubMed]
69. Peters-Golden, M.; Brock, T.G. Intracellular compartmentalization of leukotriene synthesis: Unexpected nuclear secrets. FEBS Lett. 2001, 487, 323-326. [CrossRef]
70. Hennig, R.; Grippo, P.; Ding, X.Z.; Rao, S.M.; Buchler, M.W.; Friess, H.; Talamonti, M.S.; Bell, R.H.; Adrian, T.E. 5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions. Cancer Res. 2005, 65, 6011-6016. [CrossRef] [PubMed]
71. Mohammed, A.; Janakiram, N.B.; Madka, V.; Brewer, M.; Ritchie, R.L.; Lightfoot, S.; Kumar, G.; Sadeghi, M.; Patlolla, J.M.; Yamada, H.Y.; et al. Targeting pancreatitis blocks tumor-initiating stem cells and pancreatic cancer progression. Oncotarget 2015, 6, 15524-15539. [PubMed]
72. Brunner, T.B.; Geiger, M.; Grabenbauer, G.G.; Lang-Welzenbach, M.; Mantoni, T.S.; Cavallaro, A.; Sauer, R.; Hohenberger, W.; McKenna, W.G. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J. Clin. Oncol. 2008, 26, 2699-2706. [CrossRef] [PubMed]
73. Ito, D.; Fujimoto, K.; Mori, T.; Kami, K.; Koizumi, M.; Toyoda, E.; Kawaguchi, Y.; Doi, R. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int. J. Cancer 2006, 118, 2337-2343. [CrossRef] [PubMed]
74. Javle, M.M.; Shroff, R.T.; Xiong, H.; Varadhachary, G.A.; Fogelman, D.; Reddy, S.A.; Davis, D.; Zhang, Y.; Wolff, R.A.; Abbruzzese, J.L. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: Results of two phase II studies. BioMed Cent. Cancer 2010, 10, 368. [CrossRef] [PubMed]
75. Mohammed, A.; Qian, L.; Janakiram, N.B.; Lightfoot, S.; Steele, V.E.; Rao, C.V. Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/1 LSL-KrasG12D/1 mice. Int. J. Cancer 2012, 131, 1951-1962. [CrossRef] [PubMed]
76. Liao, J.; Chung, Y.T.; Yang, A.L.; Zhang, M.; Li, H.; Zhang, W.; Yan, L.; Yang, G.Y. Atorvastatin Inhibits Pancreatic Carcinogenesis and Increases Survival in LSL-KrasG12D-LSL-Trp53R172H-Pdx1-Cre Mice. Mol. Carcinog. 2013, 52, 739-750. [CrossRef] [PubMed]
77. Mohammed, A.; Janakiram, N.B.; Brewer, M.; Ritchie, R.L.; Marya, A.; Lightfoot, S.; Steele, V.E.; Rao, C.V. Antidiabetic drug metformin prevents progression of pancreatic cancer by targeting in part cancer stem cells and mTOR signaling. Transl. Oncol. 2013, 6, 649-659. [CrossRef] [PubMed]
78. Yu, Z.; Zhong, W.; Tan, Z.M.; Wang, L.Y.; Yuan, Y.H. Gemcitabine adjuvant therapy for resected pancreatic cancer: A meta-analysis. Am. J. Clin. Oncol. 2015, 38, 322-325. [CrossRef] [PubMed]
79. Reni, M.; Cereda, S.; Milella, M.; Novarino, A.; Passardi, A.; Mambrini, A.; Di Lucca, G.; Aprile, G.; Belli, C.; Danova, M.; et al. Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial. Eur. J. Cancer 2013, 49, 3609-3615. [CrossRef] [PubMed]
80. Sporn, M.B. Combination chemoprevention of cancer. Nature 1980, 287, 107-108. [CrossRef] [PubMed]
81. Frei, E., 3rd. Combination cancer therapy: Presidential address. Cancer Res. 1972, 32, 2593-2607. [PubMed]
82. Morton, J.P.; Karim, S.A.; Graham, K.; Timpson, P.; Jamieson, N.; Athineos, D.; Doyle, B.; McKay, C.; Heung, M.Y.; Oien, K.A.; et al. Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 2010, 139, 292-303. [CrossRef] [PubMed]
83. Fendrich, V.; Chen, N.M.; Neef, M.; Waldmann, J.; Buchholz, M.; Feldmann, G.; Slater, E.P.; Maitra, A.; Bartsch, D.K. The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Gut 2010, 59, 630-637. [CrossRef] [PubMed]
84. Liby, K.T.; Royce, D.B.; Risingsong, R.; Williams, C.R.; Maitra, A.; Hruban, R.H.; Sporn, M.B. Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. Cancer Prev. Res. 2010, 3, 1427-1434. [CrossRef] [PubMed]
85. G12D mice by vitamin E δ-tocotrienol. Carcinogenesis 2013, 34, 858-863. [CrossRef] [PubMed]
86. R172H; Pdx-1-Cre(KPC) Transgenic Mouse Model of Pancreatic Cancer. Cancer Prev. Res. 2013, 6, 1074-1083. [CrossRef] [PubMed]
87. Miyabayashi, K.; Ijichi, H.; Mohri, D.; Tada, M.; Yamamoto, K.; Asaoka, Y.; Ikenoue, T.; Tateishi, K.; Nakai, Y.; Isayama, H.; et al. Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. Cancer Res 2013, 73, 2221-2234. [CrossRef] [PubMed]
88. Courtin, A.; Richards, F.M.; Bapiro, T.E.; Bramhall, J.L.; Neesse, A.; Cook, N.; Krippendorff, B.F.; Tuveson, D.A.; Jodrell, D.I. Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. PLoS ONE 2013, 8, e67330. [CrossRef] [PubMed]
89. Mohammed, A.; Janakiram, N.B.; Brewer, M.; Biddick, L.; Lightfoot, S.; Steele, V.E.; Rao, C.V. Targeting COX-LOX and EGFR pathways simultaneously by licofelone and gefitinib lead to complete blockade of progression of PanINs to pancreatic ductal adenocarcinoma. Cancer Res. 2012, 72, 1005. [CrossRef]
90. Spano, J.P.; Chodkiewicz, C.; Maurel, J.; Wong, R.; Wasan, H.; Barone, C.; Létourneau, R.; Bajetta, E.; Pithavala, Y.; Bycott, P.; et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: An open-label randomized phase II study. Lancet 2008, 371, 2101-2108. [CrossRef]
91. Kindler, H.L.; Ioka, T.; Richel, D.; Bennouna, J.; Létourneau, R.; Okusaka, T.; Funakoshi, A.; Furuse, J.; Park, Y.S.; Ohkawa, S.; et al. Axitinib plus gemcitabine vs. placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: A double-blind randomized phase 3 study. Lancet Oncol. 2011, 12, 256-262. [CrossRef]
92. O'Reilly, E.M.; Niedzwiecki, D.; Hall, M.; Hollis, D.; Bekaii-Saab, T.; Pluard, T.; Douglas, K.; Abou-Alfa, G.K.; Kindler, H.L.; Schilsky, R.L.; et al. A cancer and leukemia group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist 2010, 15, 1310-1319. [CrossRef] [PubMed]
93. Nakai, Y.; Isayama, H.; Ijichi, H.; Sasaki, T.; Sasahira, N.; Hirano, K.; Kogure, H.; Kawakubo, K.; Yagioka, H.; Yashima, Y.; et al. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br. J. Cancer 2010, 103, 1644-1648. [CrossRef] [PubMed]
94. Song, H.; Han, B.; Park, C.K.; Kim, J.H.; Jeon, J.Y.; Kim, I.G.; Kim, H.J.; Jung, J.Y.; Kim, J.H.; Kwon, J.H.; et al. Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer. Cancer Chemother. Pharmacol. 2013, 72, 845-852. [CrossRef] [PubMed]
95. Ueda, A.; Hosokawa, A.; Ogawa, K.; Yoshita, H.; Ando, T.; Kajiura, S.; Fujinami, H.; Kawai, K.; Nishikawa, J.; Tajiri, K.; et al. Treatment outcome of advanced pancreatic cancer patients who are ineligible for a clinical trial. OncoTargets Ther. 2013, 8, 491-496. [CrossRef] [PubMed]
96. Heinrich, S.; Kraft, D.; Staib-Sebler, E.; Schwarz, W.; Gog, C.; Vogl, T.; Lorenz, M. Phase II Study on Combined Intravenous and Intra-Arterial Chemotherapy with Gemcitabine and Mitomycin C in Patients with Advanced Pancreatic Cancer. Hepatogastroenterology 2013, 60, 1492-1496. [PubMed]
97. Moretto, R.; Raimondo, L.; De Stefano, A.; Cella, C.A.; Matano, E.; de Placido, S.; Carlomagno, C. FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: A monoinstitutional experience. Anticancer Drugs 2013, 24, 980-985. [CrossRef] [PubMed]
98. Van Buren, G., 2nd; Ramanathan, R.K.; Krasinskas, A.M.; Smith, R.P.; Abood, G.J.; Bahary, N.; Lembersky, B.C.; Shuai, Y.; Potter, D.M.; Bartlett, D.L.; et al. Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma. Ann. Surg. Oncol. 2013, 20, 3787-3793. [CrossRef] [PubMed]
99. Chao, Y.; Wu, C.Y.; Wang, J.P.; Lee, R.C.; Lee, W.P.; Li, C.P. A randomized controlled trial of gemcitabine plus cisplatin vs. gemcitabine alone in the treatment of metastatic pancreatic cancer. Cancer Chemother. Pharmacol. 2013, 72, 637-642. [CrossRef] [PubMed]
100. Vaccaro, V.; Bria, E.; Sperduti, I.; Gelibter, A.; Moscetti, L.; Mansueto, G.; Ruggeri, E.M.; Gamucci, T.; Cognetti, F.; Milella, M. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World J. Gastroenterol. 2013, 28, 4511-4519. [CrossRef] [PubMed]
101. Fensterer, H.; Schade-Brittinger, C.; Müller, H.H.; Tebbe, S.; Fass, J.; Lindig, U.; Settmacher, U.; Schmidt, W.E.; Märten, A.; Ebert, M.P.; et al. Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP). Ann. Oncol. 2013, 24, 2576-2581. [CrossRef] [PubMed]
102. Ma, W.W.; Hidalgo, M. The winning formulation: The development of Paclitaxel in pancreatic cancer. Clin. Cancer Res. 2013, 19, 5572-5579. [CrossRef] [PubMed]
103. Zhang, D.S.; Wang, D.S.; Wang, Z.Q.; Wang, F.H.; Luo, H.Y.; Qiu, M.Z.; Wang, F.; Li, Y.H.; Xu, R.H. Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer. Cancer Chemother. Pharmacol. 2013, 71, 1065-1072. [CrossRef] [PubMed]
104. Ko, A.H.; Tempero, M.A.; Shan, Y.S.; Su, W.C.; Lin, Y.L.; Dito, E.; Ong, A.; Wang, Y.W.; Yeh, C.G.; Chen, L.T. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br. J. Cancer 2013, 109, 920-925. [CrossRef] [PubMed]
105. Chung, J.W.; Jang, H.W.; Chung, M.J.; Park, J.Y.; Park, S.W.; Chung, J.B.; Song, S.Y.; Bang, S. Folfox4 as a rescue chemotherapy for gemcitabine-refractory pancreatic cancer. Hepatogastroenterology 2013, 60, 363-367. [PubMed]
106. Kim, Y.J.; Lee, W.J.; Woo, S.M.; Kim, T.H.; Han, S.S.; Kim, B.H.; Moon, S.H.; Kim, S.S.; Koh, Y.H.; Park, S.J.; et al. Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer. Radiat. Oncol. 2013, 8, 160. [CrossRef] [PubMed]
107. Herman, J.M.; Fan, K.Y.; Wild, A.T.; Hacker-Prietz, A.; Wood, L.D.; Blackford, A.L.; Ellsworth, S.; Zheng, L.; Le, D.T.; de Jesus-Acosta, A.; et al. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 2013, 86, 678-685. [CrossRef] [PubMed]
108. Lloyd, S.; Chang, B.W. A comparison of three treatment strategies for locally advanced and borderline resectable pancreatic cancer. J. Gastrointest. Oncol. 2013, 4, 123-130. [PubMed]
109. Kim, E.J.; Ben-Josef, E.; Herman, J.M.; Bekaii-Saab, T.; Dawson, L.A.; Griffith, K.A.; Francis, I.R.; Greenson, J.K.; Simeone, D.M.; Lawrence, T.S.; et al. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer 2013, 119, 2692-2700. [CrossRef] [PubMed]
110. Faris, J.E.; Blaszkowsky, L.S.; McDermott, S.; Guimaraes, A.R.; Szymonifka, J.; Huynh, M.A.; Ferrone, C.R.; Wargo, J.A.; Allen, J.N.; Dias, L.E.; et al. FOLFIRINOX in locally advanced pancreatic cancer: The Massachusetts General Hospital Cancer Center experience. Oncologist 2013, 18, 543-548. [CrossRef] [PubMed]
111. Nakai, Y.; Isayama, H.; Ijichi, H.; Sasaki, T.; Takahara, N.; Ito, Y.; Matsubara, S.; Uchino, R.; Yagioka, H.; Arizumi, T.; et al. A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Investig. New Drugs 2013, 31, 1294-1299. [CrossRef] [PubMed]
112. Khalil, M.A.; Qiao, W.; Carlson, P.; George, B.; Javle, M.; Overman, M.; Varadhachary, G.; Wolff, R.A.; Abbruzzese, J.L.; Fogelman, D.R. The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Investig. New Drugs 2013, 31, 1375-1383. [CrossRef] [PubMed]
113. Rougier, P.; Riess, H.; Manges, R.; Karasek, P.; Humblet, Y.; Barone, C.; Santoro, A.; Assadourian, S.; Hatteville, L.; Philip, P.A. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. Eur. J. Cancer 2013, 49, 2633-2642. [CrossRef] [PubMed]
114. El-Hadaad, H.A.; Wahba, H.A. Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. J. Gastrointest. Cancer 2013, 44, 313-317. [CrossRef] [PubMed]
115. Azmy, A.; Abdelwahab, S.; Yassen, M. Oxaliplatin and bolus-modulated 5-fluorouracil as a second-line treatment for advanced pancreatic cancer: Can bolus regimens replace FOLFOX When considered for second line? ISRN Oncol. 2013, 2013. [CrossRef] [PubMed]
116. Sohal, D.P.; Metz, J.M.; Sun, W.; Giantonio, B.J.; Plastaras, J.P.; Ginsberg, G.; Kochman, M.L.; Teitelbaum, U.R.; Harlacker, K.; Heitjan, D.F.; et al. Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer. Cancer Chemother. Pharmacol. 2013, 71, 1485-1491. [CrossRef] [PubMed]
117. Hubner, R.A.; Worsnop, F.; Cunningham, D.; Chau, I. Gemcitabine plus capecitabine in unselected patients with advanced pancreatic cancer. Pancreas 2013, 42, 511-515. [CrossRef] [PubMed]
118. Heinemann, V.; Ebert, M.P.; Laubender, R.P.; Bevan, P.; Mala, C.; Boeck, S. Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br. J. Cancer 2013, 108, 766-770. [CrossRef] [PubMed]
119. Welsh, J.L.; Wagner, B.A.; van't Erve, T.J.; Zehr, P.S.; Berg, D.J.; Halfdanarson, T.R.; Yee, N.S.; Bodeker, K.L.; Du, J.; Roberts, L.J., 2nd; et al. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): Results from a phase I clinical trial. Cancer Chemother. Pharmacol. 2013, 71, 765-775. [CrossRef] [PubMed]
120. López, R.; Méndez, C.M.; Fernández, M.J.; Reinoso, C.R.; Aldana, G.Q.; Fernández, M.S.; de LA Cámara Gómez, J.; López, M.R.; Vázquez, M.R.; Folgar, S.C. Phase II trial of erlotinib plus capecitabine as first-line treatment for metastatic pancreatic cancer (XELTA study). Anticancer Res. 2013, 33, 717-723. [PubMed]
121. Infante, J.R.; Arkenau, H.T.; Bendell, J.C.; Rubin, M.S.; Waterhouse, D.; Jones, G.T.; Spigel, D.R.; Lane, C.M.; Hainsworth, J.D.; Burris, H.A., 3rd. Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: A Sarah Cannon Research Institute phase II trial. Cancer Biol. Ther. 2013, 14, 340-346. [CrossRef] [PubMed]
122. Gunturu, K.S.; Yao, X.; Cong, X.; Thumar, J.R.; Hochster, H.S.; Stein, S.M.; Lacy, J. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: Single institution retrospective review of efficacy and toxicity. Med. Oncol. 2013, 30, 361. [CrossRef] [PubMed]
123. Tian, W.; Ding, W.; Kim, S.; Xu, X.; Pan, M.; Chen, S. Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: A meta-analysis. Pancreatology 2013, 13, 415-422. [CrossRef] [PubMed]
124. Gourgou-Bourgade, S.; Bascoul-Mollevi, C.; Desseigne, F.; Ychou, M.; Bouché, O.; Guimbaud, R.; Bécouarn, Y.; Adenis, A.; Raoul, J.L.; Boige, V.; et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ACCORD 11 randomized trial. J. Clin. Oncol. 2013, 31, 23-29. [CrossRef] [PubMed]
125. Olszewski, A.J.; Grossbard, M.L.; Chung, M.S.; Chalasani, S.B.; Malamud, S.; Mirzoyev, T.; Kozuch, P.S. Phase I study of oxaliplatin in combination with gemcitabine, irinotecan and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas. J. Gastrointest. Cancer 2013, 44, 182-189. [CrossRef] [PubMed]
126. Rose, D.P.; Connolly, J.M. Regulation of tumor angiogenesis by dietary fatty acids and eicosanoids. Nutr. Cancer 2000, 37, 119-127. [CrossRef] [PubMed]
127. Ge, Y.; Chen, Z.H.; Kang, Z.B.; Cluette-Brown, J.; Laposata, M.; Kang, J.X. Effects of adenoviral gene transfer of C. elegans n-3 fatty acid desaturase on the lipid profile and growth of human breast cancer cells. Anticancer Res. 2002, 22, 537-543. [PubMed]
128. Yang, P.; Chan, D.; Felix, E.; Cartwright, C.; Menter, D.G.; Madden, T.; Klein, R.D.; Fischer, S.M.; Newman, R.A. Formation and antiproliferative effect of prostaglandin E(3) from eicosapentaenoic acid in human lung cancer cells. J. Lipid Res. 2004, 45, 1030-1039. [CrossRef] [PubMed]
129. Gago-Dominguez, M.; Yuan, J.M.; Sun, C.L.; Lee, H.P.; Yu, M.C. Opposing effects of dietary n-3 and n-6 fatty acids on mammary carcinogenesis: The Singapore Chinese Health Study. Br. J. Cancer 2003, 89, 1686-1692. [CrossRef] [PubMed]
130. Maillard, V.; Bougnoux, P.; Ferrari, P.; Jourdan, M.L.; Pinault, M.; Lavillonnière, F.; Body, G.; Le Floch, O.; Chajès, V. N-3 and N-6 fatty acids in breast adipose tissue and relative risk of breast cancer in a case-control study in Tours, France. Int. J. Cancer 2002, 98, 78-83. [CrossRef] [PubMed]
131. Xia, S.; Wang, J.D.; Kang, J.X. Decreased n-6/n-3 fatty acid ratio reduces the invasive potential of human lung cancer cells by down-regulation of cell adhesion/invasion-related genes. Carcinogenesis 2005, 26, 779-784. [CrossRef] [PubMed]
132. Granados, S.; Quiles, J.L.; Gil, A.; Ramírez-Tortosa, M.C. Dietary lipids and cancer. Nutr. Hospitalaria 2006, 21, 42-54.
133. Simopoulos, A.P. Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: Nutritional implications for chronic diseases. Biomed. Pharmacother. 2006, 60, 502-507. [CrossRef] [PubMed]
134. Strouch, M.J.; Ding, Y.; Salabat, M.R.; Melstrom, L.G.; Adrian, K.; Quinn, C.; Pelham, C.; Rao, S.; Adrian, T.E.; Bentrem, D.J.; et al. A High omega-3 fatty acid diet mitigates murine pancreatic precancer development. J. Surg. Res. 2011, 165, 75-81. [CrossRef] [PubMed]
135. G12D/+mice. Neoplasia 2012, 14, 1249-1259. [CrossRef] [PubMed]
136. +/−-driven pancreatic cancer: The role of insulin-like growth factor-I. Cancer Prev. Res. 2013, 6, 1046-1055. [CrossRef] [PubMed]
137. Lanza-Jacoby, S.; Yan, G.; Radice, G.; LePhong, C.; Baliff, J.; Hess, R. Calorie restriction delays the progression of lesions to pancreatic cancer in the LSL-KrasG12D; Pdx-1/Cre mouse model of pancreatic cancer. Exp. Biol. Med. 2013, 238, 787-797. [CrossRef] [PubMed]
138. Lashinger, L.M.; Malone, L.M.; McArthur, M.J.; Goldberg, J.A.; Daniels, E.A.; Pavone, A.; Colby, J.K.; Smith, N.C.; Perkins, S.N.; Fischer, S.M.; et al. Genetic reduction of insulin-like growth factor-1 mimics the anticancer effects of calorie restriction on cyclooxygenase-2-driven pancreatic neoplasia. Cancer Prev. Res. 2011, 4, 1030-1040. [CrossRef] [PubMed]
139. Philip, B.; Roland, C.L.; Daniluk, J.; Liu, Y.; Chatterjee, D.; Gomez, S.B.; Ji, B.; Huang, H.; Wang, H.; Fleming, J.B.; et al. A High-Fat Diet Activates Oncogenic Kras and COX2 to Induce Development of Pancreatic Ductal Adenocarcinoma in Mice. Gastroenterology 2013, 145, 1449-1458. [CrossRef] [PubMed]
140. Dawson, D.W.; Hertzer, K.; Moro, A.; Donald, G.; Chang, H.H.; Go, V.L.; Pandol, S.J.; Lugea, A.; Gukovskaya, A.S.; Li, G.; et al. High-fat, high-calorie diet promotes early pancreatic neoplasia in the conditional KrasG12D mouse model. Cancer Prev. Res. 2013, 6, 1064-1073. [CrossRef] [PubMed]
141. Arshad, A.; Chung, W.Y.; Steward, W.; Metcalfe, M.S.; Dennison, A.R. Reduction in circulating pro-angiogenic and pro-inflammatory factors is related to improved outcomes in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega-3 fish oil. HPB 2013, 15, 428-432. [CrossRef] [PubMed]
142. Barber, M.; Fearon, K. Tolerance and incorporation of a high-dose eicosapentaenoic acid diester emulsion by patients with pancreatic cancer cachexia. Lipids 2001, 36, 347-351. [CrossRef] [PubMed]
143. Anand, P.; Kunnumakkara, A.B.; Newman, R.A.; Aggarwal, B.B. Bioavailability of curcumin: Problems and promises. Mol. Pharmacol. 2007, 4, 807-818. [CrossRef] [PubMed]
144. Kanai, M.; Yoshimura, K.; Asada, M.; Imaizumi, A.; Suzuki, C.; Matsumoto, S.; Nishimura, T.; Mori, Y.; Masui, T.; Kawaguchi, Y.; et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother. Pharmacol. 2011, 68, 157-164. [CrossRef] [PubMed]
145. Padhye, S.; Banerjee, S.; Chavan, D.; Pandye, S.; Swamy, K.V.; Ali, S.; Li, J.; Dou, Q.P.; Sarkar, F.H. Fluorocurcumins as cyclooxygenase-2 inhibitor: Molecular docking, pharmacokinetics and tissue distribution in mice. Pharm. Res. 2009, 26, 2438-2445. [CrossRef] [PubMed]
146. Dhillon, N.; Aggarwal, B.B.; Newman, R.A.; Wolff, R.A.; Kunnumakkara, A.B.; Abbruzzese, J.L.; Ng, C.S.; Badmaev, V.; Kurzrock, R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res. 2008, 14, 4491-1499. [CrossRef] [PubMed]
147. ®) in cancer patients. Cancer Chemother. Pharmacol. 2013, 71, 1521-1530. [CrossRef] [PubMed]
148. G12D mice. Carcinogenesis 2011, 32, 1689-1696. [CrossRef] [PubMed]
149. G12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS ONE 2011, 6, e16530. [CrossRef] [PubMed]
150. Wang, J.; Zhang, W.; Sun, L.; Yu, H.; Ni, Q.X.; Risch, H.A.; Gao, Y.T. Green tea drinking and risk of pancreatic cancer: A large-scale, population-based case-control study in urban Shanghai. Cancer Epidemiol. 2012, 36, 354-358. [CrossRef] [PubMed]
151. Braga, M.; Bissolati, M.; Rocchetti, S.; Beneduce, A.; Pecorelli, N.; di Carlo, V. Oral preoperative antioxidants in pancreatic surgery: A double-blind, randomized, clinical trial. Nutrition 2012, 28, 160-164. [CrossRef] [PubMed]
152. Plate, J.M. Advances in therapeutic vaccines for pancreatic cancer. Discov. Med. 2012, 75, 89-94.
153. Beatty, G.L.; Chiorean, E.G.; Fishman, M.P.; Saboury, B.; Teitelbaum, U.R.; Sun, W.; Huhn, R.D.; Song, W.; Li, D.; Sharp, L.L.; et al. CD40 Agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331, 1612-1616. [CrossRef] [PubMed]
154. Leach, D.R.; Krummel, M.F.; Allison, J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271, 1734-1736. [CrossRef] [PubMed]
155. Salama, A.K.; Hodi, F.S. Cytotoxic T-lymphocyte-associated antigen-4. Clin. Cancer Res. 2011, 17, 4622-4628. [CrossRef] [PubMed]
156. Royal, R.E.; Levy, C.; Turner, K.; Mathur, A.; Hughes, M.; Kammula, U.S.; Sherry, R.M.; Topalian, S.L.; Yang, J.C.; Lowy, I.; et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 2010, 33, 828-833. [CrossRef] [PubMed]
157. Okazaki, T.; Honjo, T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 2006, 27, 195-201. [CrossRef] [PubMed]
158. Cheever, M.A.; Allison, J.P.; Ferris, A.S.; Finn, O.J.; Hastings, B.M.; Hecht, T.T.; Mellman, I.; Prindiville, S.A.; Viner, J.L.;Weiner, L.M.; et al. The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res. 2009, 15, 5323-5337. [CrossRef] [PubMed]
159. Hollingsworth, M.A.; Swanson, B.J. Mucins in cancer: Protection and control of the cell surface. Nat. Rev. Cancer 2004, 4, 45-60. [CrossRef] [PubMed]
160. Ramanathan, R.K.; Lee, K.M.; McKolanis, J.; Hitbold, E.; Schraut, W.; Moser, A.J.; Warnick, E.; Whiteside, T.; Osborne, J.; Kim, H.; et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol. Immunother. 2005, 54, 254-264. [CrossRef] [PubMed]
161. Yamamoto, K.; Ueno, T.; Kawaoka, T.; Hazama, S.; Fukui, M.; Suehiro, Y.; Hamanaka, Y.; Ikematsu, Y.; Imai, K.; Oka, M.; et al. MUC1 Peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer Res. 2005, 25, 3575-3580. [PubMed]
162. Soares, M.M.; Mehta, V.; Finn, O.J. Three different vaccines based on the 140-amino acid MUC1 Peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type vs. MUC1-transgenic mice with different potential for tumor rejection. J. Immunol. 2001, 166, 6555-6563. [CrossRef] [PubMed]
163. Rowse, G.J.; Tempero, R.M.; VanLith, M.L.; Hollingsworth, M.A.; Gendler, S.J. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res. 1998, 58, 315-321. [PubMed]
164. Lepisto, A.J.; Moser, A.J.; Zeh, H.; Lee, K.; Bartlett, D.; McKolanis, J.R.; Geller, B.A.; Schmotzer, A.; Potter, D.P.; Whiteside, T.; et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther. 2008, 6, 955-964. [PubMed]
165. Beatty, P.L.; Narayanan, S.; Gariépy, J.; Ranganathan, S.; Finn, O.J. Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis associated colon cancer. Cancer Prev. Res. 2010, 3, 438-446. [CrossRef] [PubMed]
166. Plassmeier, L.; Knoop, R.; Waldmann, J.; Kesselring, R.; Buchholz, M.; Fichtner-Feigl, S.; Bartsch, D.K.; Fendrich, V. Aspirin prolongs survival and reduces the number of Foxp3+ regulatory T cells in a genetically engineered mouse model of pancreatic cancer. Langenbecks Arch. Surg. 2013, 398, 989-996. [CrossRef] [PubMed]
167. Liu, H.; Yuan, S.J.; Chen, Y.T.; Xie, Y.B.; Cui, L.; Yang, W.Z.; Yang, D.X.; Tian, Y.T. Preclinical evaluation of herpes simplex virus armed with granulocyte-macrophage colony-stimulating factor in pancreatic carcinoma. World J. Gastroenterol. 2013, 19, 5138-5143. [CrossRef] [PubMed]
168. Beatty, G.L.; Torigian, D.A.; Chiorean, E.G.; Saboury, B.; Brothers, A.; Alavi, A.; Troxel, A.B.; Sun, W.; Teitelbaum, U.R.; Vonderheide, R.H.; et al. A Phase I Study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin. Cancer Res. 2013, 19, 6286-6295. [CrossRef] [PubMed]
169. Le, D.T.; Lutz, E.; Uram, J.N.; Sugar, E.A.; Onners, B.; Solt, S.; Zheng, L.; Diaz, L.A., Jr.; Donehower, R.C.; Jaffee, E.M.; et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J. Immunother. 2013, 36, 382-389. [CrossRef] [PubMed]
170. Homma, Y.; Taniguchi, K.; Nakazawa, M.; Matsuyama, R.; Mori, R.; Takeda, K.; Ichikawa, Y.; Tanaka, K.; Endo, I. Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer. Clin. Transl. Oncol. 2014, 16, 330-335. [CrossRef] [PubMed]
171. Yutani, S.; Komatsu, N.; Yoshitomi, M.; Matsueda, S.; Yonemoto, K.; Mine, T.; Noguchi, M.; Ishihara, Y.; Yamada, A.; Itoh, K.; et al. A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients. Oncol. Rep. 2013, 30, 1094-1100. [CrossRef] [PubMed]
172. Ikemoto, T.; Shimada, M.; Iwahashi, S.; Saito, Y.; Kanamoto, M.; Mori, H.; Morine, Y.; Imura, S.; Utsunomiya, T. Changes of immunological parameters with administration of Japanese Kampo medicine (Juzen-Taihoto/TJ-48) in patients with advanced pancreatic cancer. Int. J. Clin. Oncol. 2014, 19, 81-86. [CrossRef] [PubMed]
173. Hardacre, J.M.; Mulcahy, M.; Small, W.; Talamonti, M.; Obel, J.; Krishnamurthi, S.; Rocha-Lima, C.S.; Safran, H.; Lenz, H.J.; Chiorean, E.G. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: A phase 2 study. J. Gastrointest. Surg. 2013, 17, 94-100. [CrossRef] [PubMed]
174. Niu, L.; Chen, J.; He, L.; Liao, M.; Yuan, Y.; Zeng, J.; Li, J.; Zuo, J.; Xu, K. Combination treatment with comprehensive cryoablation and immunotherapy in metastatic pancreatic cancer. Pancreas 2013, 42, 1143-1149. [CrossRef] [PubMed]
175. McCaffery, I.; Tudor, Y.; Deng, H.; Tang, R.; Suzuki, S.; Badola, S.; Kindler, H.L.; Fuchs, C.S.; Loh, E.; Patterson, S.D.; et al. Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor. Clin. Cancer Res. 2013, 19, 4282-4289. [CrossRef] [PubMed]
176. Takahashi, R.; Hirata, Y.; Sakitani, K.; Nakata, W.; Kinoshita, H.; Hayakawa, Y.; Nakagawa, H.; Sakamoto, K.; Hikiba, Y.; Ijichi, H.; et al. Therapeutic effect of c-Jun N-terminal kinase inhibition on pancreatic cancer. Cancer Sci. 2013, 104, 337-344. [CrossRef] [PubMed]
177. Chugh, R.; Sangwan, V.; Patil, S.P.; Dudeja, V.; Dawra, R.K.; Banerjee, S.; Schumacher, R.J.; Blazar, B.R.; Georg, G.I.; Vickers, S.M.; et al. A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Sci. Transl. Med. 2012, 17, 156ra139. [CrossRef] [PubMed]
178. Lampson, B.L.; Kendall, S.D.; Ancrile, B.B.; Morrison, M.M.; Shealy, M.J.; Barrientos, K.S.; Crowe, M.S.; Kashatus, D.F.; White, R.R.; Gurley, S.B.; et al. Targeting eNOS in pancreatic cancer. Cancer Res. 2012, 72, 4472-4482. [CrossRef] [PubMed]
179. Singh, M.; Lima, A.; Molina, R.; Hamilton, P.; Clermont, A.C.; Devasthali, V.; Thompson, J.D.; Cheng, J.H.; Bou Reslan, H.; Ho, C.C.; et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat. Biotechnol. 2010, 28, 585-593. [CrossRef] [PubMed]
180. Singh, M.; Couto, S.S.; Forrest, W.F.; Lima, A.; Cheng, J.H.; Molina, R.; Long, J.E.; Hamilton, P.; McNutt, A.; Kasman, I.; et al. Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models. J. Pathol. 2012, 227, 417-430. [CrossRef] [PubMed]
181. Plentz, R.; Park, J.S.; Rhim, A.D.; Abravanel, D.; Hezel, A.F.; Sharma, S.V.; Gurumurthy, S.; Deshpande, V.; Kenific, C.; Settleman, J.; et al. Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 2009, 136, 1741-1749. [CrossRef] [PubMed]
182. Feldmann, G.; Maitra, A. Molecular Genetics of Pancreatic Ductal Adenocarcinomas and Recent Implications for Translational Efforts. J. Mol. Diagn. 2008, 10, 111-122. [CrossRef] [PubMed]
183. Eser, S.; Reiff, N.; Messer, M.; Seidler, B.; Gottschalk, K.; Dobler, M.; Hieber, M.; Arbeiter, A.; Klein, S.; Kong, B.; et al. Selective Requirement of PI3K/PDK1 Signaling for Kras Oncogene-Driven Pancreatic Cell Plasticity and Cancer. Cancer Cell 2013, 23, 406-420. [CrossRef] [PubMed]
184. Mohammed, A.; Janakiram, N.B.; Madka, V.; Ritchie, R.L.; Brewer, M.; Biddick, L.; Patlolla, J.M.; Sadeghi, M.; Lightfoot, S.; Steele, V.E.; et al. Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling. Cancer Prev. Res. 2014, 7, 1198-1209. [CrossRef] [PubMed]
185. Renouf, D.J.; Moore, M.J.; Hedley, D.; Gill, S.; Jonker, D.; Chen, E.; Walde, D.; Goel, R.; Southwood, B.; Gauthier, I.; et al. A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. Investig. New Drugs 2012, 30, 779-786. [CrossRef] [PubMed]
186. Alvarez, R.; Musteanu, M.; Garcia-Garcia, E.; Lopez-Casas, P.P.; Megias, D.; Guerra, C.; Muñoz, M.; Quijano, Y.; Cubillo, A.; Rodriguez-Pascual, J.; et al. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br. J. Cancer 2013, 109, 926-933. [CrossRef] [PubMed]
187. Neesse, A.; Frese, K.K.; Bapiro, T.E.; Nakagawa, T.; Sternlicht, M.D.; Seeley, T.W.; Pilarsky, C.; Jodrell, D.I.; Spong, S.M.; Tuveson, D.A. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc. Natl. Acad. Sci. USA 2013, 110, 12325-12330. [CrossRef] [PubMed]
188. Cabral, H.; Murakami, M.; Hojo, H.; Terada, Y.; Kano, M.R.; Chung, U.I.; Nishiyama, N.; Kataoka, K. Targeted therapy of spontaneous murine pancreatic tumors by polymeric micelles prolongs survival and prevents peritoneal metastasis. Proc. Natl. Acad. Sci. USA 2013, 110, 11397-11402. [CrossRef] [PubMed]
189. Yip-Schneider, M.T.; Wu, H.; Stantz, K.; Agaram, N.; Crooks, P.A.; Schmidt, C.M. Dimethylaminoparthenolide and gemcitabine: A survival study using a genetically engineered mouse model of pancreatic cancer. BMC Cancer 2013, 17, 194. [CrossRef] [PubMed]
190. Wu, C.; Fernandez, S.A.; Criswell, T.; Chidiac, T.A.; Guttridge, D.; Villalona-Calero, M.; Bekaii-Saab, T.S. Disrupting cytokine signaling in pancreatic cancer: A phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease. Pancreas 2013, 42, 813-818. [CrossRef] [PubMed]
191. Mitsunaga, S.; Ikeda, M.; Shimizu, S.; Ohno, I.; Furuse, J.; Inagaki, M.; Higashi, S.; Kato, H.; Terao, K.; Ochiai, A. Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer 2013, 108, 2063-2069. [CrossRef] [PubMed]